Feasibility study of stem-cell enriched autologous lipotransfer to treat oro-facial fibrosis in systemic sclerosis (Sys-Stem): Protocol for open-label randomised controlled trial

Jeon, Faith Hyun Kyung; Denton, Christopher P.; Butler, Peter E. M.

doi:10.1016/j.isjp.2020.07.002

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The French SSc national cohort study database received ethical approval from CCTIRS (approval no. 13.145; Advisory Committee on Information Processing in Material Research in the Field of Health). Data protection complied with the requirements of the National Information Science and Liberties Commission (no.…”

Section: Ethical Approvalmentioning

confidence: 99%

“…Overall, 34%, 31% and 4% of patients were positive for anti-topoisomerase I antibodies (ATA), anti-centromere antibodies (ACA) and anti-RNA polymerase III antibodies (ARA), respectively. The median [IQR] mRSS was 7 [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17], 3 [2][3][4][5][6][7] and 17 [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26], for SSc, lcSSc and dcSSc patients, respectively. The frequency of baseline MO is in Fig.…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…It is easily assessed because it requires measuring only inter-incisive distance (IID). As such, MO has been commonly used as an outcome measure in SSc face rehabilitation [7][8][9] or face intervention trials [10][11][12][13]. Of note, most of these studies showed that MO could improve following physical or surgical interventions, which suggests a sensitivity to change for MO.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mouth opening in systemic sclerosis: A longitudinal analysis from the French national cohort study

Chaigne,

Bense,

Agard

et al. 2023

J Intern Med

View full text Add to dashboard Cite

BackgroundFew studies have evaluated mouth opening (MO) in systemic sclerosis (SSc). None have studied MO trajectories.ObjectiveTo study MO trajectories in SSc.MethodsThis multicentre study included patients enrolled in the French national SSc cohort with at least one MO assessment, described patients based on MO baseline measure, modelled MO trajectories and associated MO measures with SSc prognosis.ResultsWe included 1101 patients. Baseline MO was associated with disease severity. On Kaplan–Meier analysis, MO <30 mm was associated with worse 30‐year‐survival (p < 0.01) and risk of pulmonary arterial hypertension (p < 0.05). Individual MO trajectories were heterogenous among patients. The best model of MO trajectories according to latent‐process mixed modelling showed that 88.8% patients had a stable MO trajectory and clustered patients into three groups that predicted SSc survival (p < 0.05) and interstitial lung disease (ILD) occurrence (p < 0.05). The model highlighted a cluster of 9.5% patients with diffuse cutaneous SSc (dcSSc) (p < 0.05) and high but decreasing MO over 1 year (p < 0.0001) who were at increased risk of poor survival and ILD.ConclusionMO, which is a simple and reliable measure, could be used to predict disease severity and survival in SSc. Although MO remained stable in most SSc patients, dcSSc patients with high but decreasing MO were at risk of poor survival and ILD.

show abstract

Section: Ethical Approvalmentioning

confidence: 99%